A.M. Newtson

452 total citations
28 papers, 300 citations indexed

About

A.M. Newtson is a scholar working on Reproductive Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, A.M. Newtson has authored 28 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Reproductive Medicine, 15 papers in Cancer Research and 12 papers in Molecular Biology. Recurrent topics in A.M. Newtson's work include Ovarian cancer diagnosis and treatment (16 papers), Cancer-related molecular mechanisms research (11 papers) and Endometrial and Cervical Cancer Treatments (8 papers). A.M. Newtson is often cited by papers focused on Ovarian cancer diagnosis and treatment (16 papers), Cancer-related molecular mechanisms research (11 papers) and Endometrial and Cervical Cancer Treatments (8 papers). A.M. Newtson collaborates with scholars based in United States and China. A.M. Newtson's co-authors include Eric J. Devor, Kimberly K. Leslie, Jesús González Bosquet, Kristina W. Thiel, Michael J. Goodheart, David Bender, Henry Reyes Pineda, Jianling Bi, Megan McDonald and Bruce A. Smith and has published in prestigious journals such as Scientific Reports, International Journal of Molecular Sciences and Molecular Cancer.

In The Last Decade

A.M. Newtson

27 papers receiving 298 citations

Peers

Countries citing papers authored by A.M. Newtson

Since Specialization

Citations

This map shows the geographic impact of A.M. Newtson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.M. Newtson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.M. Newtson more than expected).

Fields of papers citing papers by A.M. Newtson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.M. Newtson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.M. Newtson. The network helps show where A.M. Newtson may publish in the future.

Co-authorship network of co-authors of A.M. Newtson

This figure shows the co-authorship network connecting the top 25 collaborators of A.M. Newtson. A scholar is included among the top collaborators of A.M. Newtson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.M. Newtson. A.M. Newtson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identifying ovarian cancer with machine learning DNA methylation pattern analysis 2025 ·Scientific Reports ·Jesús González Bosquet, (unknown), (unknown), Henry Reyes Pineda, A.M. Newtson, David Bender, Michael J. Goodheart	0
2	Global expression analysis of endometrial cancer cells in response to progesterone identifies new therapeutic targets 2023 ·The Journal of Steroid Biochemistry and Molecular Biology ·Kristina W. Thiel, A.M. Newtson, Eric J. Devor, Yuping Zhang, (unknown), Jianling Bi, (unknown), (unknown), (unknown), (unknown), (unknown), Chad E. Grueter, Patrick Breheny, Christy R. Hagan, Miles A. Pufall, Jason Gertz, Yan Guo, Kimberly K. Leslie	2
3	Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer 2022 ·Cell Death and Disease ·Jianling Bi, Yuping Zhang, (unknown), (unknown), A.M. Newtson, Eric J. Devor, Kristina W. Thiel, Kimberly K. Leslie	14
4	Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer 2022 ·Cancers ·(unknown), Eric J. Devor, (unknown), A.M. Newtson, Kimberly K. Leslie, David Bender, Bruce A. Smith, Michael J. Goodheart, Jesús González Bosquet	4
5	Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy 2021 ·Pharmaceuticals ·Jianling Bi, (unknown), Yuping Zhang, Eric J. Devor, (unknown), A.M. Newtson, (unknown), Donna A. Santillan, Thorsten Maretzky, Kristina W. Thiel, Kimberly K. Leslie	10
6	Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing 2021 ·Cancers ·Jianling Bi, A.M. Newtson, Yuping Zhang, Eric J. Devor, Megan I. Samuelson, Kristina W. Thiel, Kimberly K. Leslie	50
7	Creation and validation of models to predict response to primary treatment in serous ovarian cancer 2021 ·Scientific Reports ·Jesús González Bosquet, Eric J. Devor, A.M. Newtson, Bruce A. Smith, David Bender, Michael J. Goodheart, Megan McDonald, Terry A. Braun, Kristina W. Thiel, Kimberly K. Leslie	18
8	Identification of Novel lncRNAs in Ovarian Cancer and Their Impact on Overall Survival 2021 ·International Journal of Molecular Sciences ·(unknown), (unknown), A.M. Newtson, Henry Reyes Pineda, Yasmin Lyons, Eric J. Devor, David Bender, Michael J. Goodheart, Jesús González Bosquet	8
9	Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy 2020 ·International Journal of Gynecological Cancer ·Yasmin A. Lyons, Henry Reyes Pineda, Megan McDonald, A.M. Newtson, Eric J. Devor, David Bender, Michael J. Goodheart, Jesús González Bosquet	34
10	Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior 2019 ·Scientific Reports ·Henry Reyes Pineda, Eric J. Devor, (unknown), A.M. Newtson, (unknown), (unknown), (unknown), Kimberly K. Leslie, Jesús González Bosquet	27
11	<p>An integrated prediction model of recurrence in endometrial endometrioid cancers</p> 2019 ·Cancer Management and Research ·(unknown), E. Salinas, A.M. Newtson, (unknown), (unknown), (unknown), Bruce A. Smith, David Bender, Michael J. Goodheart, Kristina W. Thiel, Eric J. Devor, Kimberly K. Leslie, Jesús González Bosquet	17
12	Prediction of Epithelial Ovarian Cancer Outcomes With Integration of Genomic Data 2019 ·Clinical Obstetrics & Gynecology ·A.M. Newtson, Eric J. Devor, Jesús González Bosquet	6
13	Characterization of a TP53 Somatic Variant of Unknown Function From an Ovarian Cancer Patient Using Organoid Culture and Computational Modeling 2019 ·Clinical Obstetrics & Gynecology ·Jianling Bi, Kristina W. Thiel, (unknown), Yuping Zhang, Eric J. Devor, A.M. Newtson, Michael J. Schnieders, Jesús González Bosquet, Kimberly K. Leslie	10
14	EP1128 Differential DNA methylation in High Grade Serous Ovarian Cancer (HGSOC) is associated with tumor behaviour 2019 ·(unknown), Eric J. Devor, (unknown), A.M. Newtson, (unknown), (unknown), (unknown), (unknown), Kimberly K. Leslie, Jesús González Bosquet	1
15	hCG production by mucinous adenocarcinoma of the ovary in a reproductive aged woman 2018 ·Gynecologic Oncology Reports ·(unknown), (unknown), A.M. Newtson, David Bender, Megan McDonald	4
16	Identification of clinical-molecular characteristics associated with recurrent endometrial cancer 2018 ·Gynecologic Oncology ·(unknown), E. Salinas, A.M. Newtson, Megan McDonald, Eric J. Devor, Jesús González Bosquet	1
17	Dual progestin therapy for fertility-sparing treatment of grade 2 endometrial adenocarcinoma 2017 ·Gynecologic Oncology Reports ·A.M. Newtson, (unknown), Alpa M. Nick, Shannon N. Westin	3
18	p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers 2017 ·International Journal of Oncology ·Eric J. Devor, Jesús González Bosquet, (unknown), Henry Reyes Pineda, (unknown), Brandon Schickling, A.M. Newtson, Michael J. Goodheart, Kimberly K. Leslie	15
19	Prediction of chemo-response in serous ovarian cancer 2016 ·Molecular Cancer ·Jesús González Bosquet, A.M. Newtson, (unknown), Kristina W. Thiel, Timothy Ginader, Michael J. Goodheart, Kimberly K. Leslie, Bruce A. Smith	30
20	Association analysis of a chemo-response signature identified within The Cancer Genome Atlas aimed at predicting genetic risk for chemo-response in ovarian cancer. 2016 ·PubMed ·E. Salinas, A.M. Newtson, Kimberly K. Leslie, Jesús González Bosquet	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact